Everyone is talking about Covishield, Covaxin and Sputnik V – the three Covid-19 vaccines given in India. In fact, however, there are currently many other Covid-19 vaccines in the pipeline in India.
By the end of this year, India will likely about half a dozen vaccines. This will narrow the gap between supply and demand and also lower prices.
Here you can find out everything about the new vaccines.
COVOVAX
The Pune-based Serum Institute of India (SII) manufactures the Oxford AstraZeneca vaccine under the name “Covishield”.
In addition, it also produces the protein-based Covid-19 vaccine NVX-CoV2373 under the brand name “Covovax”. This vaccine was developed by the US biotechnology company Novovax. The production of Covovax by SII has already started.
Bridging studies for Covovax are currently underway in India. As soon as Novavax receives the necessary approvals to conduct efficacy studies abroad, SII is expected to do the same in India.
Covovax is expected to be launched in two to three months. 20 million doses of the vaccine are expected to be produced by December.
HGC019
Not far from SII, Gennova Biopharmaceuticals is another company based in Pune. The company developed India’s first mRNA Covid-19 vaccine called HGC019. Phase I trials for the vaccine candidate began last month and have enrolled 120 volunteers to date.
Gennova Biopharmaceuticals has received Rs 250 crore from the government. The company’s vaccine candidate is expected to be launched early next year.
NASA vaccine
Bharat Biotechs Candidate vaccine for the nose is currently in phase I trials.
According to the manufacturer, the intranasal vaccine BBV154 generates an immune response at the site of infection (in the nasal mucosa). This helps block both the infection and the transmission of Covid-19.
Bharat Biotech, the company that also makes Covaxin, is expected to launch ten million doses of its nasal vaccine by the end of the year.
ZyCoV-D
Zydus Cadila in Gujarat produces an intradermal Covid-19 vaccine called ZyCoV-D. It is India’s first indigenous DNA vaccine candidate and is currently being tested on children.
The company is expected to deploy five million cans by the end of the year. ZyCoV-D is expected to be launched in a month. Zydus Cadila will apply for the emergency permit in two weeks.
CORBEVAX
Hyderabad-based Biological E has developed a vaccine candidate called Corbevax that is currently in Phase 3 clinical trials.
Corbevax is a protein subunit vaccine, similar to inactivated whole-cell vaccines like Covaxin, and does not contain any live parts of the virus.
The government said Thursday that it will prepay Biological E Rs 1,500 crore to reserve 30 crore cans of Corbevax.
30 million doses of Corbevax are expected to be launched between August and December. Of these, at least 7.5 crore doses will be available by September.
PTX-COVID19-B
In addition, Biological E also makes an mRNA vaccine. The company has signed a license agreement with Providence Therapeutics Holdings to manufacture the Canadian company’s mRNA Covid-19 vaccine in India.
The vaccine, named PTX-COVID19-B, is currently being developed in Canada.
JANSSEN
Biological E is also bringing Johnson and Johnson’s Covid-19 vaccine to India. The Indian company has a contract to manufacture around 600 million doses of the vaccine called Janssen.
Janssen is already approved for use in the USA, the European Union, Thailand and South Africa, among others.
SPUTNIK V
In India, six companies will produce Russia’s Covid vaccine Sputnik V. This vaccine is expected to be the most widely used in India alongside Covishield and Covaxin, depending on how its production is ramped up.
Manufacturing companies include Hetero Biopharma, Gland Pharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Serum Institute of India. Companies are well on their way to manufacturing millions of doses of the Russian vaccine to alleviate the country’s current vaccine shortage.
FOREIGN VACCINES
Indian companies also want to use their production capacities to increase the production of foreign vaccines through technology transfer.
Cipla is about to make a billion dollar advance payment for Moderna’s booster vaccine in India. Wockhardt has also announced that it will receive technology transfer of Covid-19 vaccines to manufacture two billion doses in India.
India prides itself on being the world’s pharmacy. Currently, the country’s plan to ramp up immunization capacity to vaccinate more than a billion people seems on the right track.
However, India has to adapt to challenges in the form of new variants, vulnerability of children, etc.
ALSO READ: PM Modi commends scientists for developing India-made Covid-19 vaccines in one year
ALSO READ: Punjab government withdraws decision to sell Covid vaccines to private hospitals
إرسال تعليق